Dimerix Limited (SBMJF)
| Market Cap | 116.65M -42.7% |
| Revenue (ttm) | 4.95M +1,219.9% |
| Net Income | -10.88M |
| EPS | -0.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 214 |
| Open | 0.3500 |
| Previous Close | 0.2500 |
| Day's Range | 0.3500 - 0.3500 |
| 52-Week Range | 0.2500 - 0.3500 |
| Beta | 0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About Dimerix
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia. [Read more]
Financial Performance
In fiscal year 2025, Dimerix's revenue was 5.59 million, an increase of 1271.12% compared to the previous year's 407,466. Losses were -13.25 million, -22.39% less than in 2024.
Financial numbers in AUD Financial StatementsNews
Dimerix Slides: Investor presentation
Dimerix has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Dimerix Slides: Investor presentation
Dimerix has posted slides in relation to its latest quarterly earnings report, which was published on July 26, 2026.
Mission Therapeutics Strikes $292M Deal With Dimerix For AKI Asset MTX652
(RTTNews) - Mission Therapeutics Ltd., a clinical-stage biotechnology company focused on restoring cellular health through mitochondrial quality control, has agreed to divest its Phase 2-ready candida...
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
MELBOURNE, Australia, June 16, 2026 /PRNewswire/ -- Dimerix Limited (ASX: DXB, "Dimerix") today announced that it has entered into an exclusive license agreement with Everest Medicines for the commerc...
Dimerix Slides: Investor presentation
Dimerix has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Dimerix Quarterly report: H1 2026
Dimerix has published its H1 2026 quarterly earnings report on February 25, 2026.
Dimerix Earnings release: Q2 2026
Dimerix released its Q2 2026 earnings on January 28, 2026, summarizing the period's financial results.
Dimerix Earnings release: Q1 2026
Dimerix released its Q1 2026 earnings on October 28, 2025, summarizing the period's financial results.
Dimerix Slides: Investor Presentation
Dimerix has posted slides in relation to its latest quarterly earnings report, which was published on October 20, 2025.
Dimerix Slides: Investor Presentation
Dimerix has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2025.
Dimerix Annual report: H2 2025
Dimerix has published its H2 2025 annual report on August 28, 2025.
Dimerix Transcript: Investor Update
Phase three trial for DMX-200 in FSGS is nearing full recruitment, with strong interim results and regulatory engagement for accelerated approval. Four global partners support commercialization, and significant cash reserves enable ongoing development and expansion.
Dimerix Slides: Investor Update
Dimerix has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2025.